Download PDF
Semin Vasc Med 2005; 5(3): 235-244
DOI: 10.1055/s-2005-916162
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Mechanism of Action of the Oral Direct Thrombin Inhibitor Ximelagatran

Christer Mattsson1 , Troy C. Sarich2 , Stefan C. Carlsson1
  • 1AstraZeneca, Mölndal, Sweden
  • 2AstraZeneca LP, Wilmington, Delaware
Further Information

Publication History

Publication Date:
25 August 2005 (online)

    Permissions and Reprints

ABSTRACT

Thrombin plays a central role in thrombus formation through its conversion of fibrinogen to fibrin and activation of platelets as well as amplifying its own generation by feedback activation via factors V, VIII, and XI. Consequently, thrombin represents a logical and promising target for therapeutic interventions against arterial and venous thromboembolic disorders. Ximelagatran is the first oral agent in the new class of direct thrombin inhibitors and is rapidly absorbed and bioconverted to the active moiety, melagatran, which inhibits fluid-phase and clot-bound thrombin with similar high potency. Binding to the active site of thrombin is direct and competitive and does not require the presence of co-factors. Inhibition of thrombin generation and platelet activation has been demonstrated in vitro with melagatran as well as ex vivo after oral administration of ximelagatran to healthy human volunteers. Oral ximelagatran dose dependently reduced the total thrombus area in an ex vivo flow chamber model of arterial thrombosis, reflecting the cumulative effect of inhibition of thrombin activity, thrombin generation, and platelet activation. Melagatran has also been shown to reduce thrombin-mediated inflammation in vitro. The combination of antithrombotic and anti-inflammatory activity with the practicality of oral dosing provided by ximelagatran represents an important new option for the treatment of arterial and venous thromboembolic disorders.

KEYWORDS

Oral direct thrombin inhibitors - ximelagatran - mechanism of action

REFERENCES

  • 1 Van Aken H, Bode C, Darius H et al.. Anticoagulation: the present and future.  Clin Appl Thromb Hemost. 2001;  7 195-204
    PubMedGoogle Scholar
  • 2 Linkins L A, Weitz J I. New anticoagulants.  Semin Thromb Hemost. 2003;  29 619-631
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Narayanan S. Multifunctional roles of thrombin.  Ann Clin Lab Sci. 1999;  29 275-280
    PubMedGoogle Scholar
  • 4 Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.  Thromb Haemost. 1997;  78 386-391
    PubMedGoogle Scholar
  • 5 Lorand L, Chenoweth D, Gray A. Titration of the acceptor cross-linking sites in fibrin.  Ann NY Acad Sci. 1972;  202 155-171
    PubMedGoogle Scholar
  • 6 Furie B, Furie B C, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion.  Thromb Haemost. 2001;  86 214-221
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Hughes P E, Pfaff M. Integrin affinity modulation.  Trends Cell Biol. 1998;  8 359-364
    CrossrefPubMedGoogle Scholar
  • 8 Dore M, Korthuis R J, Granger D N, Entman M L, Smith C W. P-selectin mediates spontaneous leukocyte rolling in vivo.  Blood. 1993;  82 1308-1316
    PubMedGoogle Scholar
  • 9 Ueno A, Murakami K, Yamanouchi K, Watanabe M, Kondo T. Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells.  Immunology. 1996;  88 76-81
    CrossrefPubMedGoogle Scholar
  • 10 Colotta F, Sciacca F L, Sironi M, Luini W, Rabiet M J, Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin.  Am J Pathol. 1994;  144 975-985
    PubMedGoogle Scholar
  • 11 Mutch N J, Robbie L A, Booth N A. Human thrombi contain an abundance of active thrombin.  Thromb Haemost. 2001;  86 1028-1034
    PubMedGoogle Scholar
  • 12 Granger C B, Miller J M, Bovill E G et al.. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.  Circulation. 1995;  91 1929-1935
    PubMedGoogle Scholar
  • 13 Direct Thrombin Inhibitor Trialists' Collaborative Group . Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.  Lancet. 2002;  359 294-302
    CrossrefPubMedGoogle Scholar
  • 14 Eriksson U G, Bredberg U, Hoffmann K J et al.. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.  Drug Metab Dispos. 2003;  31 294-305
    PubMedGoogle Scholar
  • 15 Gustafsson D, Antonsson T, Bylund R et al.. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.  Thromb Haemost. 1998;  79 110-118
    PubMedGoogle Scholar
  • 16 Nilsson T, Sjoling-Ericksson A, Deinum J. The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin.  J Enzyme Inhib. 1998;  13 11-29
    PubMedGoogle Scholar
  • 17 Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.  Thromb Haemost. 1997;  78 1286-1292
    PubMedGoogle Scholar
  • 18 Sarich T C, Eriksson U G, Mattsson C et al.. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.  Thromb Haemost. 2002;  87 300-305
    PubMedGoogle Scholar
  • 19 Sarich T C, Wolzt M, Eriksson U G et al.. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.  J Am Coll Cardiol. 2003;  41 557-564
    CrossrefPubMedGoogle Scholar
  • 20 Mattsson C, Björkman J A, Ulvinge J C. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis.  Fibrinolysis Proteolysis. 1997;  11 121-128
    PubMedGoogle Scholar
  • 21 Mattsson C, Björkman J A, Abrahamsson T et al.. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).  Thromb Haemost. 2002;  87 557-562
    PubMedGoogle Scholar
  • 22 Klement P, Carlsson S, Rak J et al.. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.  J Thromb Haemost. 2003;  1 587-594
    PubMedGoogle Scholar
  • 23 Mattsson C, Menschik-Lundin A, Nylander S, Gyzander E, Deinum J. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro.  Thromb Res. 2001;  104 475-486
    CrossrefPubMedGoogle Scholar
  • 24 Hemker H C, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential.  Thromb Haemost. 1993;  70 617-624
    PubMedGoogle Scholar
  • 25 Boström S L, Hansson G F, Kjaer M, Sarich T C. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.  Blood Coagul Fibrinolysis. 2003;  14 457-462
    CrossrefPubMedGoogle Scholar
  • 26 Boström S L, Dagnelid E, Hansson G FH, Ulvinge J C. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.  Blood Coagul Fibrinolysis. 2004;  15 25-30
    PubMedGoogle Scholar
  • 27 Lindhout T, Blezer R, Hemker H C. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.  Thromb Haemost. 1990;  64 464-468
    PubMedGoogle Scholar
  • 28 Sandset P M, Bendz B, Hansen J B. Physiological function of tissue factor pathway inhibitor and interaction with heparins.  Haemostasis. 2000;  30(Suppl 2) 48-56
    CrossrefPubMedGoogle Scholar
  • 29 Boström S L, Hansson G F, Sarich T C, Wolzt M. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.  Thromb Res. 2004;  113 85-91
    CrossrefPubMedGoogle Scholar
  • 30 Kahn M L, Nakanishi-Matsui M, Shapiro M J, Ishihara H, Coughlin S R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.  J Clin Invest. 1999;  103 879-887
    CrossrefPubMedGoogle Scholar
  • 31 Hagberg I A, Lyberg T. Evaluation of circulating platelet-leukocyte conjugates: a sensitive flow cytometric assay well suited for clinical studies.  Platelets. 2000;  11 151-160
    CrossrefPubMedGoogle Scholar
  • 32 Nylander S, Mattsson C. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action.  Blood Coagul Fibrinolysis. 2003;  14 159-167
    CrossrefPubMedGoogle Scholar
  • 33 Sarich T C, Osende J I, Eriksson U G et al.. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.  J Thromb Haemost. 2003;  1 999-1004
    CrossrefPubMedGoogle Scholar
  • 34 Eriksson U G, Bredberg U, Gislén K et al.. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.  Eur J Clin Pharmacol. 2003;  59 35-43
    PubMedGoogle Scholar
  • 35 Carlsson S C, Mattsson C, Eriksson U G et al.. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays.  Thromb Res. 2005;  115 9-18
    CrossrefPubMedGoogle Scholar
  • 36 Eriksson B I, Arfwidsson A C, Frison L et al.. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I MElagatran for THRombin inhibition in Orthopaedic surgery.  Thromb Haemost. 2002;  87 231-237
    PubMedGoogle Scholar
  • 37 Gustafsson D, Nystrom J, Carlsson S et al.. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.  Thromb Res. 2001;  101 171-181
    CrossrefPubMedGoogle Scholar
  • 38 Eriksson B I, Carlsson S, Halvarsson M, Risberg B, Mattsson C. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.  Thromb Haemost. 1997;  78 1404-1407
    PubMedGoogle Scholar
  • 39 Scherstén F, Wahlund G, Bjornheden T, Carlsson S, Mattsson C, Grip L. Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model.  Blood Coagul Fibrinolysis. 2003;  14 235-241
    CrossrefPubMedGoogle Scholar
  • 40 Fuentes-Prior P, Iwanaga Y, Huber R et al.. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex.  Nature. 2000;  404 518-525
    CrossrefPubMedGoogle Scholar
  • 41 Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat.  Thromb Res. 1999;  94 187-197
    PubMedGoogle Scholar
  • 42 Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.  Thromb Res. 2003;  109(Suppl 1) 9-15
    CrossrefPubMedGoogle Scholar
  • 43 Esmon C T. Crosstalk between inflammation and thrombosis.  Maturitas. 2004;  47 305-314
    CrossrefPubMedGoogle Scholar
  • 44 Özmen L, Ekdahl K N, Elgue G, Larsson R, Korsgren O, Nilsson B. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation.  Diabetes. 2002;  51 1779-1784
    PubMedGoogle Scholar
  • 45 Malhotra O P, Nesheim M E, Mann K G. The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins.  J Biol Chem. 1985;  260 279-287
    PubMedGoogle Scholar
  • 46 Franco V, Polanczyk C A, Clausell N, Rohde L E. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols.  Am J Med. 2004;  116 651-656
    CrossrefPubMedGoogle Scholar
  • 47 Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets.  Thromb Haemost. 1999;  81 396-399
    PubMedGoogle Scholar
  • 48 Blanchard R A, Furie B C, Jorgensen M, Kruger S F, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease.  N Engl J Med. 1981;  305 242-248
    PubMedGoogle Scholar
  • 49 White R H, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio.  Ann Intern Med. 1995;  122 40-42
    CrossrefPubMedGoogle Scholar
  • 50 Cushman M, Booth S L, Possidente C J, Davidson K W, Sadowski J A, Bovill E G. The association of vitamin K status with warfarin sensitivity at the onset of treatment.  Br J Haematol. 2001;  112 572-577
    CrossrefPubMedGoogle Scholar
  • 51 Chan Y C, Valenti D, Mansfield A O, Stansby G. Warfarin induced skin necrosis.  Br J Surg. 2000;  87 266-272
    CrossrefPubMedGoogle Scholar
  • 52 Bendayan P, Boccalon H, Dupouy D, Boneu B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins.  Thromb Haemost. 1994;  71 576-580
    PubMedGoogle Scholar
  • 53 Weitz J I, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.  J Clin Invest. 1990;  86 385-391
    CrossrefPubMedGoogle Scholar
  • 54 Agnelli G, Pascucci C, Cosmi B, Nenci G G. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.  Thromb Haemost. 1990;  63 204-207
    PubMedGoogle Scholar
  • 55 Serruys P W, Herrman J P, Simon R et al.. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.  N Engl J Med. 1995;  333 757-763
    CrossrefPubMedGoogle Scholar
  • 56 Weitz J I, Hirsh J. New anticoagulant drugs.  Chest. 2001;  119 95S-107S
    CrossrefPubMedGoogle Scholar

Stefan C CarlssonPh.D. 

Integrative Pharmacology, DISCOVERY, AstraZeneca R&D Mölndal

SE 431 83 Mölndal, Sweden